Mesoblast limited shares are going NUTS on trial success

Mesoblast limited (ASX:MSB) shares are soaring on its reported Phase III trial success.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in regenerative medicine hopeful Mesoblast limited (ASX: MSB) are on fire this morning after the company announced that one of its trial drugs to treat acute versus graft host disease (aGVHD) in children "had been successful in a pre-specified interim futility analysis". Mesoblast also updated the market that: "Enrolment in the 60-patient Phase 3 trial is ongoing across multiple sites in the United States, trial completion is expected in the first half of 2017, and commercial launch activities are underway".

The stock has climbed around 10% to $1.30 on the strength of the announcement.

The company does currently have a treatment for aGVHD licensed for sale in Japan and its U.S. trial is ongoing with the goal of getting the clinical data necessary to persuade the U.S. healthcare regulator that the drug should be licensed for sale in the U.S.

Given the complex science behind the business the market often struggles to interpret the meaning of Mesoblast's announcements which results in wild intra-day share price swings. However, over the long term the share price has been trending downhill from nearly $10 in 2011 to just over $1 in 2016 and there's no doubt as to why. Cash burn. The company's multiple clinical trials and operating costs are seriously expensive with the quarter ending September 30 2016 seeing US$20.8 million fly out the door with sales of just US$361,000.

Until the financials start to improve it's unlikely investors are going to keep bidding the share price higher on the basis of its potential alone. Especially when this cash-burning machine has US$60 million worth of cash left on its balance sheet with a quarterly outflow around $US20 million at recent levels.

Given the lack of revenues, Mesoblast is unlikely to find any sane bankers willing to lend it large sums of money on reasonable terms, which is why it's largely reliant on the largesse of shareholders willing to tip more capital into the business in the hope that the company will deliver on its reportedly giant potential.

Its cash burn means I don't consider it investment grade, especially when there are other highly profitable, fast-growing healthcare companies on the ASX with loads of potential. Take Sirtex Medical Limited (ASX: SRX) for instance, which is also what I would consider a higher-risk investment but with far greater potential to deliver investors superb returns on the basis of its fast growing sales and profits.

Motley Fool contributor Tom Richardson owns shares of Sirtex Medical Limited. You can find him on Twitter @tommyr345 The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »